Retina Summit to precede ARVO

Article

The Cole Eye Institute will present a Retina Summit CME symposium immediately before the ARVO 2013 annual meeting.

Cleveland-The Cole Eye Institute will present a Retina Summit at a Retina Subspecialty Day Friday, May 3, 2013, immediately before the Association for Research in Vision and Ophthalmology (ARVO) 2013 annual meeting in Seattle. The Retina Summit is a CME symposium with the aim to improve physicians’ abilities to diagnose and manage macular and vitreoretinal diseases through appropriate use of the latest ocular imaging techniques, as well as surgical and therapeutic techniques.

This full-day symposium, directed by Peter K. Kaiser, MD, will be composed of didactic presentations and interactive case-based sessions to be directed by world-renowned experts in the field. Discussion sessions will be incorporated into each section to address outstanding knowledge gaps and maximize learning gain. An emphasis will be placed on interaction between participants and faculty.

“The landscape of macular and vitreoretinal diseases is constantly evolving, providing our community with an increased need for discussion and learning opportunities,” said Dr. Kaiser, of the Cole Eye Institute, Cleveland Clinic, Cleveland, OH. “We are thrilled to be initiating the first retina subspecialty day just prior to ARVO as it provides an additional focused opportunity this year for retinal specialists as well as general ophthalmologists and ophthalmic researchers to address these changes and walk away with timely information that can be applied in their daily practice.”

The meeting is jointly sponsored by Dannemiller and Meridius Health Communications. For additional information, please visit www.retinasummit.com.

For more articles in this issue of Ophthalmology Times eReport, click here.

Related Videos
TENAYA, LUCERNE year 2 data reveals promising results for faricimab
How to diagnose geographic atrophy earlier
World Sight Day 2022: Eye care professionals share what global vision means to them
Samsara Vision update: Concerto trial recruiting patients with late-stage AMD
Understanding fluid dynamics in wet macular degeneration
YOSEMITE, RHINE treat-and-extend data show favorable results for faricimab for the treatment of DME
What are you most excited about in the field of retina? Tunde Peto, MD, PhD weighs in
Leveraging noninvasive ophthalmic imaging for patients with Alzheimer disease and analyzing UK Biobank data
EURETINA 2022: Leadership discusses what to expect, outlines Women in Retina program
DAVIO trial update: 12-month safety results indicate no serious adverse events, reduced treatment burden
© 2024 MJH Life Sciences

All rights reserved.